Antiphospholipid Syndrome Collaborative Registry (APSCORE)

This study is ongoing, but not recruiting participants.

First Received: February 2, 2004 Last Updated: March 19, 2008 History of Changes

Sponsors and Collaborators:	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Center on Minority Health and Health Disparities (NCMHD)
Information provided by:	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov Identifier:	NCT00076713

Purpose

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals.

The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.

Condition
Antiphospholipid Syndrome

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Antiphospholipid Syndrome Collaborative Registry (APSCORE)

Resource links provided by NLM:

MedlinePlus related topics: Autoimmune Diseases

U.S. FDA Resources

Further study details as provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS):

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Serum, plasma, genomic DNA

Estimated Enrollment:	2000
Study Start Date:	April 2000

Detailed Description:

Registry participants will have a blood sample drawn and will be interviewed about their medical histories. Participants will be asked to return for a follow-up visit after two years. Clinical, demographic, and laboratory data will be collected. Registry resources will be made available to researchers and medical practitioners to support a broad range of research on the causes, diagnosis, mechanisms, and treatment of APS.

The University of North Carolina at Chapel Hill is the coordinating center and an enrollment site for the registry. There are seven other enrollment sites: Ball Memorial Hospital, Muncie, IN; Duke University, Durham, NC; Hospital for Special Surgery, New York, NY; Johns Hopkins University, Baltimore, MD; Morehouse School of Medicine, Atlanta, GA; University of Texas Health Science Center, San Antonio, TX; and University of Utah Health Science Center, Salt Lake City, UT.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Specialty and subspecialty clinics

Criteria

Inclusion Criteria:

Antiphospholipid antibodies with or without associated clinical manifestations

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00076713

Locations

United States, Georgia
Morehouse School of Medicine
Atlanta, Georgia, United States, 30310
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21205
United States, New York
Hospital for Special Surgery, Weill-Cornell University Medical Center
New York, New York, United States, 10021
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Texas
University of Texas Health Science Center
San Antonio, Texas, United States, 78229
United States, Utah
University of Utah Health Science Center
Salt Lake City, Utah, United States, 84132

Sponsors and Collaborators

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Center on Minority Health and Health Disparities (NCMHD)

More Information

Additional Information:

Click here for the APSCORE Web site. This link exits the ClinicalTrials.gov site

Publications:

Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 2003 Nov;48(11):3004-8. Review. No abstract available.

Responsible Party:	University of North Carolina at Chapel Hill ( Robert A. S. Roubey, MD )
Study ID Numbers:	NIAMS-099
Study First Received:	February 2, 2004
Last Updated:	March 19, 2008
ClinicalTrials.gov Identifier:	NCT00076713 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS):

Antiphospholipid

Study placed in the following topic categories:

Autoimmune Diseases
Antiphospholipid Syndrome

Additional relevant MeSH terms:

Autoimmune Diseases
Pathologic Processes
Disease

Immune System Diseases
Syndrome
Antiphospholipid Syndrome

ClinicalTrials.gov processed this record on July 02, 2009